Long-term evolution of postpartum sacroiliac bone marrow oedema: a 5-year longitudinal follow-up study

IntroductionBone marrow oedema (BME) on MRI of the sacroiliac joints (SIJ) commonly occurs after pregnancy. Our goal was to assess the evolution of BME over a period of 5 years and the potential development of structural lesions.MethodsMRI-SIJ was performed after an uncomplicated vaginal delivery, w...

Full description

Saved in:
Bibliographic Details
Published inRheumatic & musculoskeletal diseases open Vol. 11; no. 2; p. e005309
Main Authors Varkas, Gaëlle, De Meester, Liesbet, de Hooge, Manouk, De Craemer, Ann-Sophie, Herregods, Nele, Jans, Lennart, Carron, Philippe, Elewaut, Dirk, Van den Bosch, Filip
Format Journal Article
LanguageEnglish
Published England EULAR 04.04.2025
BMJ Publishing Group LTD
BMJ Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:IntroductionBone marrow oedema (BME) on MRI of the sacroiliac joints (SIJ) commonly occurs after pregnancy. Our goal was to assess the evolution of BME over a period of 5 years and the potential development of structural lesions.MethodsMRI-SIJ was performed after an uncomplicated vaginal delivery, with a follow-up 5 years later, evaluating both inflammatory and structural lesions.Results19 women were assessed. Mean age was 35.3 years, with median body mass index of 20.8. Six subjects reported back pain, of which only one reported inflammatory back pain (IBP). No association was found between IBP and Spondyloarthritis Research Consortium of Canada (SPARCC) score (p=0.24), nor with a positive MRI according to the Assessment of SpondyloArthritis international Society (ASAS) definition at baseline (p=0.64). Thirty-two percent (6/19) presented with BME after 5 years, 3 of whom met the ASAS definition of a positive MRI-SIJ, irrespective of subsequent pregnancies. A new delivery during follow-up was linked to the total number of structural lesions at year 5, whereas mean weight gain across all pregnancies correlated with sclerosis. Sclerosis and erosions were more frequently detected by synthetic CT compared with T1-weighted MRI.ConclusionsIn postpartum women, no significant development of structural MRI lesions was observed 5 years after a single delivery, despite the presence of BME in a significant number of individuals postpartum and at follow-up. These results support the hypothesis that, unlike BME in SpA, childbirth-related mechanical stress-induced BME does not lead to structural lesions. However, subsequent pregnancies may contribute to their development.
Bibliography:Original research
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/rmdopen-2024-005309).
GV Speaker or consulting fees by AbbVie, Amgen, UCB, Pfizer, Eli Lilly, Novartis, Janssen, Galapagos, Celltrion. Educational grants: ASAS, KBVR-SRBR, Celltrion, EG. Research support: Takeda, Celltrion, Galapagos, AbbVie, MSD. MdH Speaker or consulting fees by UCB A-SDC Speaker or consulting fees by UCB. LJ Co-founder of RheumaFinder. PC Research grants from UCB, MSD and Pfizer; speaker fees or consultant fees from Pfizer, MSD, Novartis, Bristol Myers Squibb, AbbVie, UCB, Eli Lilly, Gilead and Celgene Corporation. DE Speaker or consulting fees by AbbVie, Eli Lilly, Galapagos, Janssen, Novartis, UCB, Amgen, Pfizer. FVdB. Consulting fees by AbbVie, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, UCB.
GV and LDM contributed equally.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
ISSN:2056-5933
2056-5933
DOI:10.1136/rmdopen-2024-005309